The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey

Dogan M., DEMİRKAZIK A., Tukun A., SAK S., CEYHAN K., Yalcin B., ...Daha Fazla

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.24, sa.1, ss.1-10, 2014 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.4999/uhod.13083
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-10
  • Anahtar Kelimeler: Non-Small cell lung cancer, EGFR, KRAS, BRAF, Erlotinib, GROWTH-FACTOR-RECEPTOR, ACTIVATING MUTATIONS, COLORECTAL-CANCER, RAS ONCOGENE, GEFITINIB, INHIBITION, ERLOTINIB, SURVIVAL, TRIAL, ADENOCARCINOMA
  • Ankara Üniversitesi Adresli: Evet

Özet

The aim of the study was to evaluate EGFR (axon 19 deletion, exon 21 L858R point mutation), KRAS and brat mutation rates besides their relationship with survival and response to the treatment in non small cell lung cancer (NSCLC). We evaluated 513 NSCLC patients followed-up between January 2004 and November 2009 according to our registration data, retrospectively. Only 42 advanced stage NSCLC patients had enough tumor tissue material in paraffin blocks for all mutation analysis. The patients were evaluated retrospectively for clinicopathological features, EGFR, KRAS and BRAF mutations, erlotinib treatment, time to progression (TTP) and overall survival (OS). Mutation rates were as 7.14% (two patients) for EGFR exon 19 deletion; 4.76% (one patient)for KRAS codon 61 deletion and 2.38% for BRAF V600E mutation. They had neither EGFR exon 21 point mutation nor different mutations together. Median follow-up was 26 months (5-83) for all patients. It was 43 months (23-83) for the patients who had erlotinib and 23 months (5-61) for those who did not. Ten (23.8%) patients had erlotinib. There was significant survival difference between the patients taking erlotinib and the others (28 +/- 3 months versus 15 +/- 4 months, p = 0.05). UP and OS were longer in the patients who had mutations, however the difference was not significant (p = 0.119 and p = 0.06). To our knowledge, this is the first study evaluating EGFR, KRAS and BRAF mutations in advanced stage NSCLC in Turkey.